We hypothesized to produce a powerful immune response against solid tumors by combining the antibody redirected cancer cell targeting, the CD28-CD3ζ triggered T cell activation through a CAR, and the repetitive restimulation of the retargeted T cells by engaging the endogenous B cells. This evidence concerns the gene CD28 and cancer.